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A B S T R A C T
Primary Whipple disease of the Central Nervous System is a rare entity whose outcome might be fatal if
not promptly diagnosed and treated. Few cases are reported in the literature with heterogeneous clinical
and radiological presentations which often make the diagnosis extremely challenging.
We report a case of primary Whipple disease of the Central Nervous System presenting with
rhombencephalitis in a female patient in immunosuppressive treatment for rheumatoid arthritis. We
describe the management of our patient and discuss the features of this rare clinical entity.
© 2019 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Central Nervous System (CNS) involvement during Whipple’s
disease (CNS-WD) can complicate the classic form, or less
frequently, present as a primary localization, in particular in
immunocompromised patients (Marth et al., 2016). Primary
CNS-WD is a clinical challenge, representing a life-threatening
but treatable condition. Herein, we report on an immunocompro-
mised patient who developed primary CNS-WD presenting as
rhombencephalitis, with the aim of facilitating prompt diagnosis of
this rare disease.
Case report
The patient was a 76-year-old woman admitted to our
Neurology ward because of subacute onset of diplopia, vertigo,
postural instability and headache. She had a 9-year history of
rheumatoid arthritis in treatment with methotrexate and low-dose
steroids (prednisone 2.5 mg) and reported penicillin allergy.* Corresponding author at: Infectious Diseases Unit, Fondazione IRCCS Ca’ Granda
Ospedale Maggiore Policlinico, Via Francesco Sforza 32, University of Milan, Italy.
E-mail address: andrea.gori@unimi.it (A. Gori).
https://doi.org/10.1016/j.ijid.2019.08.019
1201-9712/© 2019 The Authors. Published by Elsevier Ltd on behalf of International Soc
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).On admission, neurological examination revealed bilateral
ptosis, diplopia in all gaze positions and right dysmetria. Blood
tests showed 11520 leukocytes/mm3 with normal C-Reactive
Protein (CRP). Brain angio-CT scan was normal.
Soon after admission the patient experienced rapid conscious-
ness deterioration with cranial nerve deficits and ataxic paresis of
the right upper limb. Lumbar puncture showed crystal clear
cerebrospinal fluid (CSF) with moderate mononuclear pleocytosis
(52 cells/mm3), mildly elevated proteins (106 mg/dl) and normal
glucose. Molecular amplification for viruses (EBV-DNA, HSV1/2-
DNA, CMV-DNA, VZV-DNA, HHV6-DNA, Enterovirus-RNA, Poly-
omavirus-JC-DNA PCR), M. tuberculosis and Toxoplasma on CSF as
well as CSF culture resulted negative. Despite negative microbio-
logical results on CSF, due to increasing leukocytes (15610/mm3)
and CRP (8 mg/dL), meropenem (2 g q8h) was started. On the same
day in which antibiotics were started, signs of brainstem
involvement with tachycardia, tachypnoea, miosis and ataxic
quadriplegia appeared, requiring mechanical ventilation in
the Intensive Care Unit (ICU). During the ICU stay, brain MRI
was performed, showing multiple contrast-enhancing lesions
involving the pons, medulla and cerebellum, suggestive for
rhombencephalitis. Similar lesions involved the cervical spinal
cord and the right trigeminal nerve (see Figure 1).
Considering the radiological findings, linezolid and cotrimoxazole
were introduced to empirically cover Nocardia and Toxoplasma.iety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Figure 1. MRI showing contrast enhancing lesions in involving pons, medulla and cerebellum, suggestive for rhombencephalitis. Similar lesions are evident on the proximal
tract of the cervical spinal cord.
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Total-body CT scan also resulted normal.
During wide-spectrum antibiotic therapy, the patient experi-
enced progressive improvement of the consciousness level
allowing ICU discharge after few days. Clinical improvement
was confirmed by a brain MRI performed after 2 weeks of
antimicrobial treatment revealing a reduction of the brainstem
lesions.
CSF analysis performed after 1 month of antibiotic treatment
confirmed the general improvement (18 cells/mm3; proteins 57
mg/dL): this time, CSF was sent for further analysis including
Tropheryma whipplei-PCR, which resulted positive (genotype 2A).
After this finding, antimicrobial therapy was de-escalated by
continuing oral cotrimoxazole only (160/800 mg q12 h) and
the patient was discharged overall in good clinical condition,
although still affected by diplopia in horizontal gaze, right seventh
nerve cranial deficit and ataxic hemiparesis. After a
6-month rehabilitation course, esophagogastroduodenoscopy
was performed, showing negative Periodic Acid Schiff (PAS)
staining and T. whipplei-PCR on multiple duodenal biopsies.
Furthermore, a 6-month follow-up brain MRI showed complete
resolution of cerebral lesions, while a 12-month follow-up lumbar
puncture revealed normal CSF with negative T. whipplei-PCR.
During antibiotic treatment the patient experienced complete
resolution of ocular and cranial nerve disorders, while mild
hemiparesis persisted as long-term sequela. Cotrimoxazole was
continued for 18 months and due to rheumatoid arthritis reactiva-
tion, steroids and methotrexate were subsequently reintroduced.
The patient is currently 16 months post-antibiotics suspension in
overall discrete clinical conditions; nonetheless, follow-up is still
ongoing in order to monitor for possible relapses.
Discussion
Very few cases of primary CNS-WD confirmed by histological or
microbiological examination with consensual negative gastroin-
testinal specimens are reported in the literature (Mohamed et al.,
2011; Sung et al., 2012; Balasa et al., 2014; Panegyres et al., 2006;
Peregrin and Malikova, 2015; Giaccone et al., 2016; Tábuas-Pereira
et al., 2016; Kilani et al., 2018).
Neurological presentation of CNS-WD is heterogeneous (Marth
et al., 2016; Mohamed et al., 2011; Panegyres et al., 2006):
cognitive changes and psychiatric symptoms are common,
followed by hypothalamic symptoms, myoclonus and ataxia (Louis
et al., 1996). Ocular movement disturbance, including oculomas-
ticatory myorhythmia or oculo-facio-skeletal myorhythmiaassociated with progressive supranuclear ophthalmoplegia, are
considered pathognomonic of CNS-WD although rarely reported
(Louis et al., 1996) Overall, the triad of dementia, ophthalmoplegia
and myoclonus is considered highly suggestive (Louis et al., 1996).
Similarly, there is no typical neuro-radiologic pattern of CNS-
WD that can present with multifocal lesions often involving the
hypothalamus, thalamus, midbrain or temporal lobes (Panegyres
et al., 2006; Tábuas-Pereira et al., 2016), as well as with a focal
lesion with or without mass effect (Peregrin and Malikova, 2015;
Giaccone et al., 2016; Kilani et al., 2018) or even with normal
radiological pattern (Sung et al., 2012).
Our patient presented with some of the typical symptoms of
CNS-WD including ocular movementsdeficits and ataxia, while
brainstem involvement is quite uncommon. Listeria is the most
common cause of infectious rhombencephalitis, followed by
Enterovirus-71 (Jubelt et al., 2011), while to our knowledge, no
cases of CNS-WD presenting with rhombencephalitis have been
previously reported.
Despite being very uncommon, spinal cord involvement has
also been described in CNS-WD (Balasa et al., 2014; Gerard et al.,
2002) and our patient seems to reflect this uncommon localiza-
tion; of note, Gerard et al suggest that WD, although rare, must be
considered in case of inflammatory spinal involvement (Gerard
et al., 2002).
Immunosuppression plays a major role in predisposing to WD
(Marth et al., 2016). Notably, misdiagnosis of WD-associated
arthralgias as rheumatic disorders can lead to inappropriate
immunosuppressive therapies accelerating the natural history of
the infection (Glaser et al., 2017). In our patient, the positivity of
the anti-citrullinated peptide/protein antibodies (anti-CCP) and
the previous benefit of steroids on arthralgias made the diagnosis
of rheumatoid arthritis likely even before excluding a systemic
disease by endoscopy.
The delay in performing the duodenal biopsies is certainly a
limitation of our case report since the intestinal abnormalities
might have improved during antibiotic course. However, studies
demonstrate how even after successful eradication of T. whipplei,
the PAS-positive material in macrophages of duodenal lamina
propria can persist for several years; moreover, the endoscopic
lesions are likely to last longer than 6 months in more than 80% of
cases (Geboes et al., 1992). As recommended, multiple biopsies
were taken in our patient in order to increase the sensitivity in case
of patchy histopathological alterations (Marth et al., 2016).
Untreated WD has a fatal course. A 2-week induction phase
with ceftriaxone or meropenem followed by cotrimoxazole is
proposed as standard treatment for CNS-WD (Marth et al., 2016).
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partly associated to mutations in the folP gene encoding
dihydropteroate-synthase, the sulphonamides target (Lagier
et al., 2014). The association of doxycycline with hydroxychlor-
oquine represents a valid alternative option. Given her allergy to
penicillin, our patient was initially treated with meropenem and
afterwards with cotrimoxazole to empirically cover toxoplasma.
Hence, she luckily received an appropriate scheme for CNS-WD
even before the diagnosis was made, allowing clinical
improvement.
The duration of treatment for classic WD is usually one year, and
follow-up duodenal biopsies are warranted to monitor treatment
response (Marth et al., 2016). Differently, treatment duration for
CNS-WD remains controversial (Mohamed et al., 2011) as late
relapses have been described after antibiotics discontinuation,
associated with a severe prognosis (Marth et al., 2016); therefore
some experts recommend life-long suppression with doxycycline.
In general, a negative PCR on follow-up CSF is considered a good
marker of therapeutic efficacy (Marth et al., 2016).
The clinical improvement observed in our patient, together
with the complete resolution of radiological signs at 6-month
follow up MRI and the negativity of T.whipplei PCR on 1-year follow
up CSF, led us to discontinue cotrimoxazole after 18 months.
However, given the reintroduction of immunosuppressive
treatment for rheumatoid arthritis, the patient is being closely
monitored for potential relapse.
Conclusions
Isolated CNS-WD is a clinical challenge and should be
considered in the differential diagnosis in unusual cases of
encephalitis. Awareness among clinicians should be raised in
order to help prompt diagnosis and optimal treatment.
As the exact treatment duration of CNS-WD has not been
established, patients should be closely followed in case of
antibiotics discontinuation in order to monitor for potential
relapse, especially in case of coexisting immunosuppression.
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